Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term "pro-tumor macrophage" generally refers to a heterogeneous population of tumor-associated macrophages (TAMs) exhibiting a pro-tumoral, immunosuppressive phenotype within the tumor microenvironment (TME)[1][2][3][5]. These macrophages most closely resemble the so-called "M2" or alternatively activated macrophages and are typically characterized by high expression of surface markers like **CD206, CD163, CD36**, and the production of anti-inflammatory cytokines such as **IL-10** and **CCL18**[1][2][6]. Functionally, pro-tumor macrophages facilitate tumor progression by suppressing cytotoxic T cell responses, promoting angiogenesis (via secretion of factors like VEGF and MMP9), remodeling tissue to facilitate invasion, and enhancing metastasis through both direct and indirect mechanisms[1][2][3][4]. TAMs, especially in their pro-tumor (M2-like) states, can arise from circulating monocytes recruited into the tumor and influenced by signals from tumor cells and other immune populations, including cytokines such as IL-4, IL-10, and chemokines such as CCL2 and GM-CSF[2][6]. These cells, through their diverse secretome and modulatory capacity, are linked to worse prognosis in multiple cancers and are increasingly pursued as therapeutic targets for intervention by either depleting these cells, inhibiting their recruitment, or reprogramming them toward a more tumor-suppressive (M1-like) state[1][5]. **Note:** "Pro-tumor macrophage" is not a molecular entity but a functional and phenotypic classification of macrophages within the context of cancer. The correct canonical form is "Tumor-associated macrophage (pro-tumor phenotype)" or "Pro-tumoral M2 macrophage," which is a cell subtype, not a single gene or protein target. Consequently, targeting strategies generally focus on pathways, surface receptors, or functional phenotypes associated with these cells, not a single receptor or enzyme. If a structured molecular target is needed, consider major markers or upstream regulators (e.g., CSF-1 receptor, CCL2/CCR2 axis)[1][3][7].
Inhibition of macrophage recruitment or survival (e.g., colony-stimulating factor 1 receptor inhibition); Prevention of pro-tumor cytokine/chemokine signaling (e.g., blocking CCL2, IL-10, CCL18); Induction of repolarization from pro-tumor (M2-like) to anti-tumor (M1-like) state; Blocking angiogenic factors secreted by TAMs
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor-associated macrophage (pro-tumor phenotype) (TAM (pro-tumor)).